-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
3D Organoid Platform of InnoModels Biotechnology: Opening a New Chapter in Life Science
Author:
InnoModels
Release time:
2024-10-14
In the field of life sciences, every leap in technology leads to deeper research and medical advances. InnoModels Biotechnology (Beijing) Co., Ltd, with its innovative 3D organoid platform, is providing scientists with an unprecedented research tool, which greatly promotes drug research and development and the exploration of disease mechanisms.
1、 The Rise of 3D Organoid Platforms
Organoid, an in vitro cultured biological complex, has become a hotspot for life science research with its unique ability to simulate 3D structure and function. The 3D organoid platform of InnoModels Biotechnology, through in vitro cell culture, makes its self-organization to form a complex three-dimensional structure, which highly restores the microenvironment of human organs. This technology not only breaks through the limitations of traditional cell culture methods, but also provides a more realistic and reliable experimental model for drug development and disease modeling.
2、Excellent technical characteristics
The 3D organoid platform of InnoModels Biotechnology has a number of excellent technical features. First of all, the platform supports self-assembly of multiple cell types and can simulate complex organ structures, such as liver, heart, lungs, etc., providing a wide range of application possibilities for research in different fields. Through well-designed culture conditions and support structures, the platform is able to better restore the physiological functions of organoids, making them closer to the biological properties of in vivo organs.
In addition, the platform supports high-throughput experiments, accelerating the drug screening and evaluation process. InnoModels Biotechnology provides customers with customized experimental solutions, adapting the technology to the specific needs of the research project to ensure that scientists are able to obtain data that best meets their research goals.

3、 Wide range of applications
The 3D organoid platform of InnoModels Biotechnology has demonstrated its great potential for application in a variety of fields. In the field of drug development, the platform provides more realistic and reliable in vitro models for pre-screening and evaluation of drugs, accelerating the drug development process. By simulating the physiological structure and function of organs, researchers can assess the toxicity of potential drugs or compounds, providing a reliable basis for drug safety assessment.
In terms of disease research, the platform is able to simulate the microenvironment of a specific disease and establish a more realistic disease model, which helps scientists to study the disease mechanism in depth. For example, brain organoids can be used to simulate Zika virus infection and psychiatric disorders; liver organoids provide a powerful tool for studying hepatic steatohepatitis. In addition, organoid technology can also be applied to cancer tissue engineering, simulating the process of tumor formation or generating tumor biobanks, helping the in-depth development of cancer research.
4、 Future Prospects
Despite the remarkable achievements of current organoid technologies, many challenges and limitations still exist. For example, in vitro-generated organoids are not yet able to fully recapitulate in vivo organs in terms of cell type and cell maturity; the size of generated organoids and the lack of blood vessels, nerves, and immune systems limit their applications. However, these limitations are expected to be gradually resolved as technology continues to advance and innovate.
In the future, InnoModels Biotechnology will continue to dedicate itself to the technological development and optimization of 3D organoid platforms to promote further breakthroughs in biomedical research and applications. Combined with 3D bioprinting and other advanced technologies, we will design structures with more cell specificity and good separation characteristics, providing more possibilities for the development of organoid technology. We have reason to believe that with the promotion of companies such as InnoModels Biotechnology, organoid technology will play an even more important role in the field of life sciences and make greater contributions to the cause of human health.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd